HC Wainwright Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $72.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price raised by analysts at HC Wainwright from $70.00 to $72.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 25.35% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Piper Sandler raised their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Finally, JMP Securities upped their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Stock Down 0.6 %

HALO opened at $57.44 on Wednesday. Halozyme Therapeutics has a one year low of $36.61 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The stock has a market capitalization of $7.31 billion, a P/E ratio of 16.75, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The business’s 50-day simple moving average is $53.26 and its 200-day simple moving average is $54.58.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 165.13% and a net margin of 43.74%. Analysts anticipate that Halozyme Therapeutics will post 4.72 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently modified their holdings of the business. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the period. FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $65,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $69,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.